All In Biotech

Drug Trial Radar · NCT06289166

Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor

A Multi-center, Open-label, Phase Ⅱb Trial to Evaluate the Safety and Efficacy of STSP-0601 for Injection in Patients with Hemophilia with Inhibitor

Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Mar 18, 2024

Primary completion

Oct 17, 2024

Study completion Oct 17, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and efficacy of multiple-dose of STSP-0601 for the treatment of bleeding episodes in hemophilia A or B patients with inhibitor.

Conditions

  • Hemophilia

Interventions

  • STSP-0601 for InjectionDrug

    A Multiple-dose Design to Evaluate the Safety, Tolerability and Efficacy of STSP-0601 for Injection in hemophilia A or B patients with inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of successfully treated bleeding episodesTime frame: 12 hours after first administration of study drug

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Fujian Medical University Affiliated Union Medical College Hospital

    Fuzhou, Fujian, China

  • Lanzhou University First Hospital

    Lanzhou, Gansu, China

  • Southern Medical University Southern Hospital

    Guangzhou, Guangdong, China

  • Shenzhen Second People's Hospital

    Shenzhen, Guangdong, China

  • Guizhou Medical University Affiliated Hospital

    Guiyang, Guizhou, China

  • Harbin First Hospital Hematology Tumor Research Center

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Nanjing University School of Medicine Affiliated Gulou Hospital

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The first hospital of Jilin University

    Changchun, Jilin, China

  • Shengjing Hospital Affiliated to China Medical University

    Shenyang, Liaoning, China

  • Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Xi'an Central Hospital

    Xi’an, Shanxi, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Hospital of Hematology, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

  • The Second Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.